136 related articles for article (PubMed ID: 791476)
21. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
22. The "other" asparaginase.
Hrushesky WJ; Slavik M; Penta J; Muggia F
Med Pediatr Oncol; 1976; 2(4):441-2. PubMed ID: 794672
[No Abstract] [Full Text] [Related]
23. A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult Volunteers.
Lin T; Hernandez-Illas M; Rey A; Jenkins J; Chandula R; Silverman JA; Choi MR
Clin Transl Sci; 2021 May; 14(3):870-879. PubMed ID: 33278328
[TBL] [Abstract][Full Text] [Related]
24. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
Castaman G; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):57-60. PubMed ID: 8039761
[TBL] [Abstract][Full Text] [Related]
25. [Activity of Erwinia-asparaginase after anaphylactic reaction to Peg-asparaginase].
Viña Romero MM; García Gil S; Nazco Casariego GJ; Merino Alonso J; Gutiérrez Nicolás F
An Pediatr (Engl Ed); 2019 Mar; 90(3):187-188. PubMed ID: 29705180
[No Abstract] [Full Text] [Related]
26. Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia.
Jones B; Holland JF; Glidewell O; Jacquillat C; Weil M; Pochedly C; Sinks L; Chevalier L; Maurer HM; Koch K; Falkson G; Patterson R; Seligman B; Sartorius J; Kung F; Haurani F; Stuart M; Burgert EO; Ruymann F; Sawitsky A; Forman E; Pluess H; Truman J; Hakami N
Med Pediatr Oncol; 1977; 3(4):387-400. PubMed ID: 337095
[No Abstract] [Full Text] [Related]
27. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
Boos J
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
[TBL] [Abstract][Full Text] [Related]
28. [Long-term infusion of L-asparaginase--an alternative to intramuscular injection?].
Rodriguez T; Baumgarten E; Fengler R; Soumpasis D; Henze G
Klin Padiatr; 1995; 207(4):207-10. PubMed ID: 7564153
[TBL] [Abstract][Full Text] [Related]
29. A comparative study of the antitumor effectiveness of E. coli and Erwinia asparaginases.
Roberts J; Schmid FA; Old LJ; Stockert E
Cancer Biochem Biophys; 1976 May; 1(4):175-8. PubMed ID: 788892
[TBL] [Abstract][Full Text] [Related]
30. Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators.
Holland JF; Ohnuma T
Cancer Treat Rep; 1981; 65 Suppl 4():123-30. PubMed ID: 7049376
[TBL] [Abstract][Full Text] [Related]
31. [Increase of immunoglobulins and formation of antibodies in the course of asparaginase treatment].
Lamerz R; Fateh-Moghadam A; Hornung B; Ehrhart H
Klin Wochenschr; 1971 Mar; 49(6):360-4. PubMed ID: 4932029
[No Abstract] [Full Text] [Related]
32. L-asparaginase in treatment of acute leukaemia and lymphosarcoma.
Beard ME; Crowther D; Galton DA; Guyer RJ; Fairley GH; Kay HE; Knapton PJ; Malpas JS; Scott RB
Br Med J; 1970 Jan; 1(5690):191-5. PubMed ID: 4904933
[TBL] [Abstract][Full Text] [Related]
33. Immunological aspects of L-asparaginase treatment in children with lymphoproliferative disease.
Zajaczkowski J; Pituch A; Legutko L; Pajak E
Helv Paediatr Acta; 1976 Jan; 30(4-5):441-6. PubMed ID: 1060605
[TBL] [Abstract][Full Text] [Related]
34. Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
Figueiredo L; Cole PD; Drachtman RA
Expert Rev Hematol; 2016 Mar; 9(3):227-34. PubMed ID: 26765930
[TBL] [Abstract][Full Text] [Related]
35. ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia.
Wang B; Hak LJ; Relling MV; Pui CH; Woo MH; Storm MC
J Immunol Methods; 2000 May; 239(1-2):75-83. PubMed ID: 10821949
[TBL] [Abstract][Full Text] [Related]
36. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia.
Eden OB; Shaw MP; Lilleyman JS; Richards S
Med Pediatr Oncol; 1990; 18(6):497-502. PubMed ID: 2233523
[TBL] [Abstract][Full Text] [Related]
37. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
[TBL] [Abstract][Full Text] [Related]
38. Immunological responses to L-asparaginase.
Peterson RG; Handschumacher RE; Mitchell MS
J Clin Invest; 1971 May; 50(5):1080-90. PubMed ID: 4101590
[TBL] [Abstract][Full Text] [Related]
39. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
[TBL] [Abstract][Full Text] [Related]
40. Delayed allergic reactions following intramuscular L-asparaginase.
Spiegel RJ; Echelberger CK; Poplack DG
Med Pediatr Oncol; 1980; 8(2):123-5. PubMed ID: 6932563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
